U. Shukla

发表

Population Pharmacokinetic Analysis of Didanosine (2′,3′‐Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS‐Related Complex

F. Valentine, C. Mclaren, R. Dolin, 1992, Journal of clinical pharmacology.

Glimepiride Pharmacokinetics in Obese Versus Non-Obese Diabetic Patients

E. Chi, K. Lehr, U. Shukla, 2004, The Annals of pharmacotherapy.

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

R. Barbhaiya, U. Shukla, D. Greene, 2004, European Journal of Clinical Pharmacology.

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.

P. Kroboth, R. Barbhaiya, U. Shukla, 1995, Journal of clinical psychopharmacology.

Nefazodone pharmacokinetics: assessment of nonlinearity, intra-subject variability and time to attain steady-state plasma concentrations after dose escalation and de-escalation

P. Marathe, P. Chaikin, R. Barbhaiya, 1996, European Journal of Clinical Pharmacology.

Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration

K. Pittman, C. Gleason, W. Shyu, 1990, Antimicrobial Agents and Chemotherapy.

Comparative bioavailability study of two tablet formulations of cimetidine.

J. Wagner, E. Sakmar, R. Berardi, 1984, Biopharmaceutics & drug disposition.

Stability of trimetrexate, a new non-classical antifolate, in infusion solutions.

W. Ensminger, U. Shukla, P. Stetson, 1991, Journal of chromatography.

Acetaminophen pharmacokinetics: comparison between pregnant and nonpregnant women.

W. Rayburn, P. Stetson, U. Shukla, 1986, American journal of obstetrics and gynecology.

Comparison of the effects of food on the pharmacokinetics of cefprozil and cefaclor

K. Pittman, C. Gleason, W. Shyu, 1990, Antimicrobial Agents and Chemotherapy.

Phase I study of multiple-dose cefprozil and comparison with cefaclor

K. Pittman, C. Gleason, W. Shyu, 1990, Antimicrobial Agents and Chemotherapy.

Simultaneous determination of thymine and 5-bromouracil in DNA hydrolysates using gas chromatography-mass spectrometry with selected-ion monitoring.

J. Maybaum, P. Stetson, W. Ensminger, 1986, Journal of chromatography.

High-performance liquid chromatographic method for the determination of bromodeoxyuridine and its major metabolite, bromouracil, in biological fluids.

P. Stetson, W. Ensminger, U. Shukla, 1985, Journal of chromatography.

Pharmacokinetic Interactions of Cefprozil With Food, Propantheline, Metoclopramide, and Probenecid in Healthy Volunteers

K. Pittman, R. Barbhaiya, U. Shukla, 1992, Journal of clinical pharmacology.

Sensitive high-performance liquid chromatographic method for the determination of 5-fluorouracil in plasma.

W. Ensminger, U. Shukla, P. Stetson, 1985, Journal of chromatography.

Simultaneous High-Performance Liquid Chromatographic Analysis of Cefprozil Diastereomers in a Pharmacokinetic Study

W. Shyu, R. Barbhaiya, U. Shukla, 1991, Pharmaceutical Research.

Sensitive gas-liquid chromatographic-electron-capture detection method for determination of sobrerol in biological fluids.

J. Wagner, U. Shukla, P. Stetson, 1984, Journal of chromatography.

Nonlinear Pharmacokinetics of Nefazodone After Escalating Single and Multiple Oral Doses

S. Kaul, R. Barbhaiya, U. Shukla, 1995, Journal of clinical pharmacology.

Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses

K. Pittman, R. Barbhaiya, R. Gammans, 2004, European Journal of Clinical Pharmacology.

Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.

K. Midha, R. Barbhaiya, U. Shukla, 1996, Journal of clinical psychopharmacology.

Absorption and Presystemic Metabolism of Nefazodone Administered at Different Regions in the Gastrointestinal Tract of Humans

P. Marathe, D. Salazar, R. Barbhaiya, 1995, Pharmaceutical Research.

Single‐ and multiple‐dose pharmacokinetics of nefazodone in patients with hepatic cirrhosis

S. Sainati, D. Behr, C. Natarajan, 1995, Clinical pharmacology and therapeutics.

Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog.

P. Marathe, K. Pittman, R. Barbhaiya, 1993, Drug metabolism and disposition: the biological fate of chemicals.

PhaseIStudyofMultiple-Dose Cefprozil andComparison withCefaclor

K. Pittman, C. Gleason, W. Shyu, 1990 .

High-performance liquid chromatographic assay of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol (BMY 14802), a potential antipsychotic drug, in monkey and rat plasma.

K. Pittman, K. Dandekar, S. Kaul, 1991, Journal of Chromatography A.

Safety, Tolerance, and Preliminary Pharmacokinetics of Nefazodone After Administration of Single and Multiple Oral Doses to Healthy Adult Male Volunteers: A Double‐Blind, Phase I Study

P. Marathe, K. Pittman, R. Mayol, 1995, Journal of clinical pharmacology.

Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.

M. Folan, P. Kroboth, R. Lush, 1995, Journal of clinical psychopharmacology.

Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function

R. Barbhaiya, U. Shukla, D. Greene, 2004, European Journal of Clinical Pharmacology.

Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans.

R. Barbhaiya, U. Shukla, D. Greene, 1995, British journal of clinical pharmacology.